{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Unresectable+Breast+Carcinoma&page=2", "query": { "condition": "Locally Advanced Unresectable Breast Carcinoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Unresectable+Breast+Carcinoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T08:49:55.559Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04799249", "title": "Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "TNBC - Triple-Negative Breast Cancer", "Breast Cancer" ], "interventions": [ { "name": "Trilaciclib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "G1 Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 194, "start_date": "2021-05-14", "completion_date": "2024-05-24", "has_results": false, "last_update_posted_date": "2024-08-01", "last_synced_at": "2026-05-22T08:49:55.559Z", "location_count": 16, "location_summary": "Gilbert, Arizona • Washington D.C., District of Columbia • St. Petersburg, Florida + 13 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Clinton", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04799249" }, { "nct_id": "NCT01149083", "title": "Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Locally Advanced Breast Carcinoma", "Metastatic Breast Carcinoma", "Unresectable Breast Carcinoma" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 77, "start_date": "2010-06-30", "completion_date": "2024-09-30", "has_results": true, "last_update_posted_date": "2025-08-15", "last_synced_at": "2026-05-22T08:49:55.559Z", "location_count": 22, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 12 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01149083" }, { "nct_id": "NCT00951054", "title": "A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Triple Negative Breast Cancer" ], "interventions": [ { "name": "NK012", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nippon Kayaku Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 61, "start_date": "2009-02", "completion_date": "2015-02", "has_results": false, "last_update_posted_date": "2015-02-16", "last_synced_at": "2026-05-22T08:49:55.559Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00951054" }, { "nct_id": "NCT01304797", "title": "Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "MM-302 Monotherapy", "type": "DRUG" }, { "name": "MM-302 in combination with trastuzumab", "type": "DRUG" }, { "name": "MM-302 in combination with trastuzumab q3w", "type": "DRUG" }, { "name": "MM-302 in combination with trastuzumab and cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2011-03", "completion_date": "2017-01", "has_results": false, "last_update_posted_date": "2017-01-06", "last_synced_at": "2026-05-22T08:49:55.559Z", "location_count": 5, "location_summary": "San Francisco, California • Indianapolis, Indiana • Boston, Massachusetts + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01304797" }, { "nct_id": "NCT02751528", "title": "QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "ETBX-021", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "NantBioScience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2017-03-04", "completion_date": "2018-08-16", "has_results": true, "last_update_posted_date": "2025-01-13", "last_synced_at": "2026-05-22T08:49:55.559Z", "location_count": 2, "location_summary": "El Segundo, California • Sioux Falls, South Dakota", "locations": [ { "city": "El Segundo", "state": "California" }, { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02751528" }, { "nct_id": "NCT04862663", "title": "Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced (Inoperable) or Metastatic Breast Cancer" ], "interventions": [ { "name": "Capivasertib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 895, "start_date": "2021-05-10", "completion_date": "2029-08-14", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-05-22T08:49:55.559Z", "location_count": 52, "location_summary": "Tucson, Arizona • Fountain Valley, California • Glendale, California + 45 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04862663" }, { "nct_id": "NCT06224673", "title": "ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2 Low Breast Carcinoma", "Triple Negative Breast Cancer", "Hormone-receptor-positive Breast Cancer", "Hormone Receptor Positive Breast Carcinoma" ], "interventions": [ { "name": "ARX788", "type": "DRUG" }, { "name": "Computed Tomography (CT)", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Amiloride", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Laura Huppert, MD, BA", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2026-05-15", "completion_date": "2029-09-30", "has_results": false, "last_update_posted_date": "2026-05-01", "last_synced_at": "2026-05-22T08:49:55.559Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06224673" }, { "nct_id": "NCT00301899", "title": "Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "pertuzumab", "type": "BIOLOGICAL" }, { "name": "trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2005-12", "completion_date": "2007-10", "has_results": false, "last_update_posted_date": "2012-03-08", "last_synced_at": "2026-05-22T08:49:55.559Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00301899" }, { "nct_id": "NCT02614794", "title": "A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2 Positive Breast Cancer" ], "interventions": [ { "name": "tucatinib", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "trastuzumab", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 612, "start_date": "2016-01-28", "completion_date": "2022-08-11", "has_results": true, "last_update_posted_date": "2023-08-14", "last_synced_at": "2026-05-22T08:49:55.559Z", "location_count": 81, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 66 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02614794" }, { "nct_id": "NCT03184558", "title": "Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Triple Negative Breast Cancer", "Inflammatory Breast Cancer Stage IV" ], "interventions": [ { "name": "Bemcentinib; pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BerGenBio ASA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2017-07-26", "completion_date": "2018-08-20", "has_results": true, "last_update_posted_date": "2021-11-09", "last_synced_at": "2026-05-22T08:49:55.559Z", "location_count": 5, "location_summary": "Duarte, California • San Diego, California • Kansas City, Missouri + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03184558" } ] }